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Abstract
An enzymatic approach, based on a transglutaminase-catalyzed coupling reaction, was investigated to modify bovine liver
catalase with an end-group aminated dextran derivative. We demonstrated that catalase activity increased after enzymatic gly-
cosidation and that the conjugate was 3.8-fold more stable to thermal inactivation at 55 ◦C and 2-fold more resistant to proteolytic
degradation by trypsin. Moreover, the transglutaminase-mediated modification also improved the pharmacokinetics behavior
of catalase, increasing 2.5-fold its plasma half-life time and reducing 3-fold the total clearance after its i.v. administration in
rats.
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. Introduction
During last decades, several proteins obtained from
atural sources or through recombinant techniques
ave been evaluated as potential therapeutic drugs
n different diseases. However, rapid clearance after
n vivo administration, which is mediated by dif-
erent mechanisms such as the recognition by the
∗ Corresponding author. Tel.: +39 081 2539470;
ax: +39 081 2539473.
E-mail address: portaraf@unina.it (R. Porta).
immune system, proteolytic degradation, removal from
the bloodstream by the liver and glomerular filtration
through the kidney, currently limits the clinical appli-
cation of the majority of the protein drugs (Caliceti and
Veronese, 2003).
Chemical modification with biocompatible poly-
mers constitutes a well-probed method for improving
the pharmacokinetics properties of these bioactive
polypeptides (Veronese and Morpurgo, 1999). In
this respect, circulatory half-life of proteins has
been increased by conjugation with natural and
synthetic polymers such as poly(ethylene glycol)
168-1656/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
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(PEG) (Veronese and Morpurgo, 1999; Kartre,
1993; Veronese, 2001; Fuertges and Abuchowski,
1990), dextran (Fujita et al., 1992), polyvinyl
pyrrolidone (Caliceti et al., 1995), poly(styrene-
co-maleic anhydride) (SMA) (Maeda, 2001),
poly(divinyl ether-co-maleic anhydride) (DIVEMA)
(Caliceti et al., 1996; Hirano et al., 1997), and
N-(2-hydroxypropyl)methacrylamide (Ulbrich et al.,
2000). Among these, PEG has been the polymer most
extensively used due to the possibility to synthesize
end-group activated PEG derivatives, able to give
rise to polymer–protein conjugates with defined
composition through site-specific chemical reactions
(Caliceti and Veronese, 2003; Veronese and Morpurgo,
1999; Kartre, 1993; Veronese, 2001; Fuertges and
Abuchowski, 1990; Roberts et al., 2002). However,
PEG is a non biodegradable macromolecule slowly
cleared from the human body and in addition the
occurrence of anaphylactic reactions and severe
bronchospasm have been reported after treatment with
PEG-modified enzymes (Ho et al., 1986). On the other
hand, chemical treatments often reduce the therapeutic
effectiveness of the transformed proteins (Veronese,
2001), and the toxicity of the reagents commonly
employed to synthesize polymer–protein conjugates
forces to carry out arduous purification schemes to
obtain adducts for biomedical applications. Therefore,
the synthesis of new end-group functionalized deriva-
tives of biodegradable macromolecules, as well as the
development of alternative coupling procedures for
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Mancuso et al., 2001) and proteins (Porta et al., 1990;
Mancuso et al., 1996; Tufano et al., 1996) by covalently
linking polyamines to their reactive endo-glutamine
residues.
In the present paper we describe a novel procedure
for preparing a dextran–catalase conjugate by using
TGase. In this sense, the synthesis of an end-group
activated dextran derivative and its site-specific enzy-
matic attachment to the reactive glutamine residues
of catalase (EC 1.11.1.6) is reported. Dextran is
a natural and biodegradable polysaccharide widely
employed in biomedical fields (Mehvar, 2000), includ-
ing the cross-linking of bioactive proteins (Fujita et al.,
1992; Marshall and Humphreys, 1979). On the other
hand, catalase is an antioxidant enzyme with potential
application in the therapy of several diseases medi-
ated by reactive oxygen species (Shaked and Wolfe,
1988).
2. Materials and methods
2.1. Materials
Bovine liver catalase was purchased from Roche
Molecular Biochemistry (Mannheim, Germany). Dex-
tran 5000 was obtained from Serva (Heidelberg, Ger-
many). TGase (8 U/mg based on the hydroxamate
activity assay (Folk and Chung, 1985) from Streptover-
ticillium sp. was obtained from Ajinomoto Co. (Japan).
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Rreparing polymer-protein prodrugs, are receiving an
ncreased attention in pharmacological sciences.
Recently we reported an enzymatic approach
or synthesizing several trypsin–cyclodextrin com-
lexes with improved catalytic and stability proper-
ies by using the enzyme transglutaminase (TGase,
C 2.3.2.13) (Villalonga et al., 2003a,b). TGase pro-
uces either intra- or intermolecular isopeptide bonds
etween the -carboxamide group of endoprotein glu-
amine residues acting as acyl donor and the -
mino group of endoprotein lysine residues which acts
s acyl acceptor (Aeschlimann and Paulsson, 1994).
eactive lysines may be also substituted by several
ow molecular weight compounds containing primary
mino groups, giving rise to a variety of protein-(-
lutamyl) derivatives (Folk and Chung, 1985). Thus,
Gase has been employed to modify the biologi-
al activities of same peptides (Esposito et al., 1999;ovine pancreatic trypsin and Fractogel EMD BioSEC
S) were obtained from Merck (Darmstadt, Germany).
ll other chemicals were analytical grade.
.2. TGase acyl donor substrate activity of
atalase
The occurrence of reactive acyl donor glutamine
esidues in the catalase protein structure was assayed
y a fluorometric method (Folk and Chung, 1985)
ased on the incorporation of monodansylcadaverin
MDC) as acyl acceptor. The composition of the reac-
ion mixtures is described in the legend of Fig. 1.
he separation of MDC from the reaction products
nd the visualization of the latter were achieved by
DS/PAGE (Laemmli, 1970) and ultraviolet illumi-
ation on a Fluor-S Multilmager apparatus (BioRad,
ichmond, USA).
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Fig. 1. TGase-dependent incorporation of MDC into catalase. Cata-
lase (400g) was incubated for 2 h at 37 ◦C in 70l of 100 mM
sodium phosphate buffer, pH 7.0, with TGase (40g) in the pres-
ence (lanes 2 and 3) or absence (lanes 1) of 20 mM MDC control
(lane 2) was boiled at 100 ◦C for 10 min after TGase addition. The
mixtures were incubated at room temperature for 1 h. At the end
of incubation the reactions were stopped by addition of 900l of
a solution of 9 M urea, 2% (m/v) SDS and 40 mM dithiothreitol in
50 mM Tris–HCl buffer, pH 7.1, and aliquots (20l) of the samples
analyzed by 12% SDS/PAGE. The gel was visualized by Coomassie
staining (A) and ultraviolet illumination (B). St = Molecular weight
standards: -galactosidase from E. coli (150 kDa), phosphorylase B
from rabbit muscle (100 kDa), bovine serum albumin (75 kDa), hen
egg white ovalbumin (50 kDa), bovine carbonic anhydrase (37 kDa)
and soybean trypsin inhibitor (25 kDa).
2.3. Synthesis of end-group aminated dextran
Dextran (2 g), dissolved in 10 ml distilled water, was
treated with 1 ml hexylenediamine and stirred during
2 h. About 150 mg NaCNBH3 was then added, and
the reaction mixture was continuously stirred at room
temperature overnight. The solution was then exten-
sively dialyzed versus distilled water using a Spectra-
por 6 dialysis tubing (Serva, molecular weight cut-off
1000 Da) and finally lyophilized. The aminated dextran
derivative was characterized by 1H NMR spectrometry
using a Bruker AVANTE 500 MHz apparatus.
2.4. TGase-catalyzed synthesis of
catalase–dextran conjugate
TGase (40g) was added to 4 ml of 20 mM sodium
phosphate buffer, pH 7.0, containing 200 mg of dextran
and 8 mg catalase. The reaction mixture was stirred at
37 ◦C for 2 h and then applied to a gel filtration column
Fractogel EMD BioSEC (S) (2.6 cm × 60 cm) equi-
librated in 20 mM sodium phosphate buffer, pH 7.0,
containing 100 mM NaCl. The fractions containing the
polymer–enzyme conjugate were pooled and kept at
4 ◦C. The molecular weight of this conjugate was deter-
mined by analytical gel permeation chromatography
(GPC) on TSK G3000 column (7.5 cm × 60 cm), cali-
brated with protein standards from the MW-GF-1000
kit (Sigma, USA).
2.5. Assays
Catalase activity was determined spectrophotomet-
rically at 240 nm and 37 ◦C by the rate of decomposi-
tion of H2O2 in 20 mM sodium phosphate buffer, pH
7.0 (Chance and Maehley, 1955). Protein concentra-
tion was estimated as described by Lowry et al. (1951)
using bovine serum albumin as standard. Total carbo-
hydrates were determined by the phenol-sulfuric acid
method (Dubois et al., 1956) using glucose as standard.
2.6. Kinetics of thermal inactivation of proteolysis
by trypsin
Native and dextran-modified catalase preparations
were incubated at 55 ◦C in 20 mM sodium phos-
phate buffer, pH 7.0 (1 mg protein/ml). Aliquots were
removed at scheduled times, chilled quickly, and
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essayed for enzymatic activity.
Different catalase preparations were incubated
t 37 ◦C in 50 mM Tris–HCl buffer, pH 8.0
1 mg protein/ml) in the presence of 20g trypsin
0.72 U). Aliquots were removed at scheduled times
nd assayed for enzymatic activity.
.7. Pharmacokinetic studies
Native and dextran-modified catalase preparations
ere administered intravenously (50 000 U/kg) in the
ail vein of female Winstar rats (250–300 g, six ani-
als per each group). Blood samples (500l) were
ollected at scheduled times with heparinized cap-
llary syringes from the ocular plexus, centrifuged
nd assayed for catalase activity. Endogenous catalase
ctivity was previously evaluated in each animal before
nzyme inoculation. The plasma level of all enzyme
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forms as a function of time was analyzed by a two-
compartment model, fitting the experimental data to the
equation C(t) = Ae−αt + Be−βt (Fujita et al., 1990), and
assuming as 100% the initial enzymatic activity deter-
mined in the blood plasma after intravenous adminis-
tration. The pharmacokinetic parameters A, B, α and
β were calculated by using a non-linear regression
procedure based on the Marquardt-Levenberg method
of iterative convergence included into the Microcal
Origin 7.0 software (Microcal Software, Inc., MA,
USA). The other parameters were calculated as fol-
low: half-life in phase, t1/2(α) = (ln 2)/α; half-life in β
phase, t1/2(β) = (ln 2)/β; area under the plasma concen-
tration curve, AUC = A/α + B/β; total body clearance,
CLtotal = dose/AUC.
2.8. Statistical methods
Microcal Origin 7.0 software (Microcal Software,
Inc., MA, USA) was used for all statistical analyses.
The data were analyzed by ANOVA, and means were
compared using Student’s t-test. Differences were con-
sidered to be significant at p < 0.05.
3. Results
With the aim of evaluating the ability of bovine liver
catalase to act as acyl donor substrate of microbial
TGase, the incorporation of an aminated fluorescent
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Fig. 2. TGase-mediated modification of catalase with end-group
activated dextran analyzed by 12% SDS/PAGE. Lanes: (1) cata-
lase, (2) catalase + TGase, (3) catalase + aminated dextran + TGase
thermically inactivated, (4) catalase + aminated dextran + TGase, (St)
molecular weight standards (as in Fig. 1). The reaction conditions
are reported in Section 2.
through the formation of amide bonds using the enzyme
TGase as coupling agent. The synthesis of the aminated
dextran–catalase conjugate was demonstrated by SDS-
PAGE, as shown by the occurrence in the lane 4 of
Fig. 2, indicated by the arrow, of a protein band with a
higher molecular mass than of unmodified catalase. In
addition, no intermolecular cross-links between cata-
lase molecules were detected after catalase treatment
with TGase in the absence of the polymer (Fig. 2, lane
2). The aminated dextran–catalase adduct, was eluted
as a single peak, containing carbohydrates and catalytic
activity, from a gel filtration on Fractogel EMD BioSec
(S) (data not shown).
Table 1 reports some structural and catalytic proper-
ties of native and TGase-modified catalase. The carbo-
hydrate content of the conjugated catalase, determined
by the colorimetric quantification of the attached d-
glucose units, represented about 8.0% by weight of the
dextran-modified enzyme form. According to the aver-
age molecular weight of the polysaccharide, this result
represented an average of 4 mol of dextran per mol of
protein, corresponding to 1 mol of polymer attached toarker (MDC) into its polypeptide chain was first
nvestigated. Lane 3 of the Panel B of Fig. 1 shows
he presence of a fluorescent band with the same elec-
rophoretical mobility of catalase, indicating that the
nzyme is able to act as a TGase amino-acceptor sub-
trate.
The strategy employed in this work for end-group
unctionalization of dextran involves its treatment with
molar excess of hexylenediamine in the presence
f sodium cyanoborohydride, in order to reduce only
he new imine bonds formed at the reducing end of
he polymer. This procedure has been previously used
or preparing end-group activated pullulan derivatives
Bruneel and Schacht, 1995). The aminated dextran
ave satisfactory 1H NMR spectra.
The activated dextran was further attached to the
lutamine residues located at the protein surface of
ovine liver catalase, under very mild conditions,
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Table 1
Structural and catalytic properties of native and modified catalase
Enzyme Polymer content (mol/mol protein) Molecular weight (kDa) Specific activity (U/g)
Catalase – 238 14.6
Aminated dextran–catalase 4 260 15.5
each protein subunit. This result is in agreement with
the molecular weight determined for this catalase neo-
glycoconjugate by GPC. Moreover, the specific activity
of catalase was found slightly increased after its enzy-
matic glycosidation with aminated dextran.
The site-specific glycosidation of catalase with the
end-group aminated dextran derivative yields also to
several positive changes in the functional stability and
pharmacokinetics properties of the enzyme. Fig. 3
shows the kinetics of thermal inactivation of native and
dextran-modified catalase at 55 ◦C and pH 7.0. During
1 h of incubation, both native and modified enzyme lost
activity progressively with time according to a first-
order kinetics, whereas the half-life of the transformed
enzyme was increased from 50 min to 3.2 h in compar-
ison with the native counterpart.
Fig. 4 depicts the time-course of proteolytic inac-
tivation of native and modified catalase by trypsin at
pH 8.0 and 30 ◦C. Although both enzyme preparations
showed a similar inactivation pattern after treatment
with the endoprotease, the aminated dextran–catalase
adduct seems to be more resistant to proteolytic inacti-
vation. In this respect, t1/2 of the glycosidated catalase
was calculated to be two-fold higher than that of native
enzyme.
F
c
Fig. 4. Kinetics of tryptic degradation of native (©) and modified
catalase () at pH 8.0. Experimental details are given in the text.
Fig. 5 reports the pharmacokinetics behavior of
native and dextran-conjugated catalase after intra-
venous administration in rats. A biphasic elimination
pattern from plasma was observed for both catalase
preparations. Thus, the pharmacokinetics parame-
ters were calculated assuming a bicompartmental
pharmacokinetics model (Table 2). Although the
Fig. 5. Pharmacokinetics profiles of native (©) and modified cata-
lase () after their i.v. administration in rats (50 000 U/kg). Experi-
mental details are given in the text.ig. 3. Kinetics of thermal inactivation of native (©) and modified
atalase () at 55 ◦C. Experimental details are given in the text.
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Table 2
Pharmacokinetics parameters of native and modified catalase after
intravenous injection in rats (50 000 U/kg)a
Parameter Catalase Aminated
dextran–catalase
Initial concentration in
the plasma (U/ml)
3.3 1.9
A 0.97 1.4
B 2.4 0.51
α 0.60 0.24
β 5.4 1.9
t1/2(α) (h) 1.2 3.0
t1/2(β) (h) 0.13 0.4
AUC (U h/ml) 2.1 6.1
CLtotal (ml/min) 110 36
a Experimental details are given in the text. The data are the means
from six independent experiments, with standard error less than 10%.
initial catalase concentration in the plasma after i.v.
administration was higher for the native preparation,
the unmodified enzyme showed a rapid clearance from
the plasma with a half-life time of about 1.2 h for the
α phase. By contrast, the dextran-conjugate catalase
disappeared more slowly from the circulation and their
t1/2(α) (3 h) and AUC (6.1 U h/ml) were significantly
higher than those of the native enzyme. Finally, the
total body clearance of the aminated dextran–catalase
adduct was also reduced showing a value about three
times lower than that of the native enzyme.
4. Discussion
Previously the beneficial effect has been reported
of chemical modification of catalase with some bio-
compatible polymers on its pharmacokinetics behav-
ior and stability properties against proteolytic degra-
dation (Marshall and Humphreys, 1979; Abuchowski
et al., 1977; Maksimenko and Tischenko, 1997). The
obtained improved characteristics favored the poten-
tial therapeutic action of polymer-modified catalase
preparations toward many injuries mediated by hydro-
gen peroxide. Among these, the beneficial effects of
the PEG–catalase complex in a rat model of lung
injury due to asbestosis have been clearly demonstrated
(Mossman et al., 1990). Treatment with PEG–catalase
conjugates also reduced both proteinuria in rats with
nephrotic syndrome (Beaman et al., 1987) and edema
i
a
mers, such as chondroitin sulfate (Maksimenko and
Tischenko, 1997) and polyaldehyde dextran (Marshall
and Humphreys, 1979), have been used as chemical
modifiers for this enzyme.
In the present work we evaluated the possibility to
employ an enzymatic approach for synthesizing a cata-
lase preparation through the site-directed incorporation
of an activated dextran derivative into the polypeptide
structure of this enzyme via a TGase-catalyzed reac-
tion. In this regard, the ability of catalase to act as acyl
donor substrate of TGase was demonstrated by test-
ing the enzymatic-mediated reactivity of its glutamine
residues towards MDC. Thus, an end-group aminated
dextran derivative was attached to catalase by using
its characteristics to act as acyl acceptor TGase sub-
strate. Therefore, an aminated dextran–catalase conju-
gate, with high purity and well-defined polymer content
and molecular weight, was obtained.
In contrast to other polymer–catalase conjugates
previously synthesized by chemical methods (Marshall
and Humphreys, 1979; Maksimenko and Tischenko,
1997), the adduct prepared by TGase-mediated reac-
tion showed an increased catalase activity in compari-
son with the native enzyme. A similar increase in the
enzymatic activity has been previously described for
cyclodextrin–trypsin conjugates obtained by a TGase-
catalyzed reaction (Villalonga et al., 2003a,b).
The enzymatic crosslink of catalase with aminated
dextran increased its resistance against thermal inac-
tivation. The improved thermostability of the enzyme
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n the optic disc of guinea pigs with acute experimental
llergic optic neuritis (Guy et al., 1994). Further poly-ould be associated with the formation of new stabi-
izing hydrogen bonds between the hydroxyl groups
f the polymer and the hydrophilic residues occur-
ing on the protein surface of the enzyme. In addition,
he TGase-catalysed attachment of dextran residues
ould also thermostabilize the conjugate by masking
he hydrophobic clusters located at the surface of cata-
ase, thus preventing both their unfavourable interac-
ion with the surrounding water molecules and the
ccurrence of protein aggregation phenomena at high
emperatures (Klibanov, 1983).
Furthermore, catalase was found to become more
esistant to tryptic degradation after the described
Gase-mediated modification. This stabilizing effect
ould be explained as a consequence of the steric
indrance determined by the attached carbohydrate
esidues, which could markedly protect the protein
rom the trypsin attack (Villalonga et al., 2003a,b).
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The pharmacokinetics performance of catalase was
also improved after TGase-catalyzed glycosidation
with aminated dextran. The increased hydrodynamic
radius of the adduct could be responsible for a reduced
glomerular filtration of the enzyme in the kidney and,
thus, for the observed increase of its t1/2 and AUC
(Lote, 2000). Moreover, the increased stability of the
aminated dextran–catalase conjugate against proteases
could also contribute to its higher half-life time and
lower clearance in comparison with the native coun-
terpart (Veronese and Morpurgo, 1999). However, it
should be noted that the observed prolongation of the
serum half-life period was lower than that detected
with the catalase adduct prepared by chemical conju-
gation with PEG residues of similar molecular weight
(Abuchowski et al., 1977). This result could be a con-
sequence of the low amount of dextran molecules cova-
lently bound to each mol of protein, due to the limited
amount of reactive glutamine residues occurring into
the catalase polypeptide chain. By contrast, dextran
biodegradability and lower toxicity, the higher catalytic
activity showed by the prepared conjugate, as well as
the benefits derived from the use of an enzyme cat-
alyzed coupling reaction, constitute important advan-
tages of the catalase glycoconjugate reported in present
paper.
5. Conclusions
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